Literature DB >> 23306109

Association between systemic non-criteria APS manifestations and antibody type and level: results from the Serbian national cohort study.

Ljudmila Stojanovich1, Milica Kontic, Aleksandra Djokovic, Dragomir Marisavljevic, Nenad Ilijevski, Natasa Stanisavljevic, Zeljko Mikovic, Milena Petkovic, Vladimir Kovcin.   

Abstract

OBJECTIVES: The aim of this study was to investigate the importance of aPL type and level for non-criteria-related events in APS patients.
METHODS: Our study included 374 patients: 260 with PAPS and 114 with APS associated with systemic lupus erythematosus (SLE).
RESULTS: We discovered significant connection between migraine and LA absence, livedo reticularis and aCL-IgG, skin ulcerations with aCL-IgG and anti-β2GPI-IgM, pseudovasculitis lesions with aCL-IgG, aCL-IgM and anti-β2GPI-IgM, and thrombocytopenia with aCL-IgM, aCL-IgG and anti-β2GPI-IgG. Thrombocytopenia occurred more frequently in patients with more than one aPL. In PAPS, epilepsy correlated with ß2GPI-IgM, migraine with aCL-IgM, and thrombocytopenia with aCL-IgM, aCL-IgG, anti ß2GPI-IgG and LA. Skin ulcerations occurred more frequently in IIc category patients and in patients with high levels of aCL-IgG and anti ß2GPI-IgG. Livedo reticularis was more prominent in PAPS with high levels of aCL-IgG. Significantly higher prevalence of thrombocytopenia was observed in patients with high levels of aCL-IgG and anti ß2GPI-IgG. Epilepsy was related to high levels of anti ß2GPI-IgM and thrombocytopenia in the SAPS was correlated with aCL-IgG. Skin ulcerations were more prevalent in aCL-IgM positive SAPS patients and epilepsy more frequently in SAPS patients with high levels of anti ß2GPI-IgG.
CONCLUSIONS: Our study showed that certain aPL type with certain level correlated with non-criteria manifestations, suggesting their predictive role.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23306109

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.

Authors:  Sebastián Udry; José Omar Latino; Cristina Belizna; Silvia Perés Wingeyer; Diego Santiago Fernández Romero; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

2.  Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome.

Authors:  Mirjana Bećarević; Marija Sarić; Ljudmila Stojanovich; Duško Mirković; Violeta Dopsaj; Svetlana Ignjatović
Journal:  Clin Rheumatol       Date:  2018-06-12       Impact factor: 2.980

3.  Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort.

Authors:  Aleksandra Djokovic; Ljudmila Stojanovich; Natasa Stanisavljevic; Sandra Djokic; Branka Filipovic; Predrag Matic; Milomir Milanovic; Svetlana Apostolovic; Jovica Saponjski
Journal:  Clin Rheumatol       Date:  2022-01-11       Impact factor: 2.980

4.  Clinical characteristics and prognosis of patients with antiphospholipid antibodies based on cluster analysis: an 8-year cohort study.

Authors:  Wanting Qi; Jiuliang Zhao; Can Huang; Nan Jiang; Jing Li; Chanyuan Wu; Shangzhu Zhang; Chaojun Hu; Dong Xu; Qian Wang; Mengtao Li; Xinping Tian; Yan Zhao; Xiaofeng Zeng
Journal:  Arthritis Res Ther       Date:  2022-06-11       Impact factor: 5.606

5.  Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome.

Authors:  Dolores Pérez; Ljudmila Stojanovich; Laura Naranjo; Natasa Stanisavljevic; Gordana Bogdanovic; Manuel Serrano; Antonio Serrano
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

Review 6.  Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms.

Authors:  Leonardo Biscetti; Gioacchino De Vanna; Elena Cresta; Ilenia Corbelli; Lorenzo Gaetani; Letizia Cupini; Paolo Calabresi; Paola Sarchielli
Journal:  J Neuroinflammation       Date:  2021-11-08       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.